MAINTENANCE OLAPARIB RECHALLENGE IN PATIENTS WITH OVARIAN CANCER PREVIOUSLY TREATED WITH A PARP INHIBITOR: DETAILED SAFETY RESULTS FROM THE PHASE IIIB OREO/ENGOT-OV38 TRIAL

Category Primary study
JournalInternational Journal of Gynecological Cancer
Year 2022
This article has no abstract
Epistemonikos ID: d3f8fcaefdbe72d01aed0c105c852cab8ef9f461
First added on: Feb 15, 2025